**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 65462

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Enhancer of zeste homolog 2 contributes to apoptosis by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in inflammatory bowel disease**

Zhou J *et al*. EZH2 in inflammatory bowel disease

Jie Zhou, Yang Yang, Yi-Ling Wang, Yue Zhao, Wen-Jing Ye, Si-Yao Deng, Jin-Yi Lang, Shun Lu

**Jie Zhou, Yi-Ling Wang, Yue Zhao, Shun Lu,** Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, Sichuan Province, China

**Yang Yang,** Department of Oncology, The Third People's Hospital of Chengdu, Chengdu 255415, Sichuan Province, China

**Wen-Jing Ye, Si-Yao Deng,** Department of School of Medicine, University of Electronic Science and Technology of China, Chengdu 397992, Sichuan Province, China

**Jin-Yi Lang,** Department of Radiological Protection, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu 229717, Sichuan Province, China

**Author contributions:** Zhou J and Yang Y performed the majority of experiments and analyzed the data; Wang YL and Zhao Y performed the molecular investigations; Ye WJ and Deng SY designed and coordinated the research; Lang JY and Lu S wrote the paper; Zhou J and Yang Y contributed equally to this work.

**Supported by** National Natural Science Foundation of China, No. 81900498.

**Corresponding author: Shun Lu, MD, Chief Physician,** Department of Radiation Oncology, Sichuan Cancer Hospital, No. 55 Renmin South Road, Chengdu 610041, Sichuan Province, China. lushousi90036@163.com

**Received:** March 7, 2021

**Revised:** April 9, 2021

**Accepted:** April 28, 2021

**Published online:** June 14, 2021

**Abstract**

BACKGROUND

Inflammatory bowel disease (IBD) is a prevalent worldwide health problem featured by relapsing, chronic gastrointestinal inflammation. Enhancer of zeste homolog 2 (EZH2) is a critical epigenetic regulator in different pathological models, such as cancer and inflammation. However, the role of EZH2 in the IBD development is still obscure.

AIM

To explore the effect of EZH2 on IBD progression and the underlying mechanism.

METHODS

The IBD mouse model was conducted by adding dextran sodium sulfate (DSS), and the effect of EZH2 on DSS-induced colitis was assessed in the model. The function of EZH2 in regulating apoptosis and permeability was evaluated by Annexin V-FITC Apoptosis Detection Kit, transepithelial electrical resistance analysis, and Western blot analysis of related markers, including Zona occludens 1, claudin-5, and occludin, in NCM460 and fetal human colon (FHC) cells. The mechanical investigation was performed by quantitative reverse transcription*-*polymerase chain reaction, Western blot analysis, and chromatin immunoprecipitation assays.

RESULTS

The colon length was inhibited in the DSS-treated mice and was enhanced by the EZH2 depletion in the system. DSS treatment caused a decreased histological score in the mice, which was reversed by EZH2 depletion. The inflammatory cytokines, such as tumor necrosis factor-α, interleukin-6, and interleukin-1β, were induced in the DSS-treated mice, in which the depletion of EZH2 could reverse this effect. Moreover, the tumor necrosis factor-α treatment induced the apoptosis of NCM460 and FHC cells, in which EZH2 depletion could reverse this effect in the cells. Moreover, the depletion of EZH2 attenuated permeability of colonic epithelial cells. Mechanically, the depletion of EZH2 or EZH2 inhibitor GSK343 was able to enhance the expression and the phosphorylation of janus kinase 2 (JK2) and signal transducer and activator of transcription in the NCM460 and FHC cells. Specifically, EZH2 inactivated JAK2 expression by regulating histone H3K27me3. JAK2 inhibitor TG101348 was able to reverse EZH2 knockdown-mediated colonic epithelial cell permeability and apoptosis.

CONCLUSION

Thus, we concluded that EZH2 contributed to apoptosis and inflammatory response by inactivating JAK2/ signal transducer and activator of transcription signaling in IBD. EZH2 may be applied as a potential target for IBD therapy.

**Key Words:** Inflammatory bowel disease; Apoptosis; Enhancer of zeste homolog 2; JAK2; Permeability; Inflammatory bowel disease therapy

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhou J, Yang Y, Wang YL, Zhao Y, Ye WJ, Deng SY, Lang JY, Lu S. Enhancer of zeste homolog 2 contributes to apoptosis by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in inflammatory bowel disease. *World J Gastroenterol* 2021; 27(22): 3073-3084

**URL:** https://www.wjgnet.com/1007-9327/full/v27/i22/3073.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i22.3073

**Core Tip:** In this study, we discovered that enhancer of zeste homolog 2 contributed to apoptosis and inflammatory response by inactivating janus kinase 2/signal transducer and activator of transcription signaling in inflammatory bowel disease (IBD). Enhancer of zeste homolog 2 may be applied as a potential target for IBD therapy.

**INTRODUCTION**

Inflammatory bowel disease (IBD) is a worldwide health problem with an increasing incidence. IBD, including Crohn’s disease and ulcerative colitis and IBD unclassified, is described as relapsing, chronic gastrointestinal inflammation[1,2]. IBD patients experience low life quality and a higher risk of colorectal cancer[3]. The critical feature of IBD is the unsolved inflammation of the intestinal field caused by a breakdown to shift from a pro-inflammatory situation to an anti-inflammatory situation[4]. Various immune cell populations, such as eosinophils, neutrophils, dendritic cells, and macrophages, are present in the intestinal mucosa, participating in inflammation during IBD[5,6]. These cells participate in inflammation by secreting chemokines, antimicrobial agents, and pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-6[3], and IL-1β[7]. Therefore, the understanding of the molecular mechanism underlying the inflammatory regulation during IBD progression is urgently needed.

The fundamental function of epigenetic systems in determining T cell lineage fate decisions has been completely defined[8,9]. Nevertheless, the effect of the histone methyltransferase enhancer of zeste homolog 2 (EZH2) has been recently identified in the process[10,11]. EZH2 serves as a methylation of histone H3K27 to H3K27me3[12]. It has been found that targeting EZH2 is able to alleviate intestinal inflammation in IBD[11]. Moreover, janus kinase 2 (JK2)/ signal transducer and activator of transcription 3 (STAT3) signaling has been identified to alleviate inflammation response during IBD[13]. However, the correlation of EZH2 with JAK2/STAT3 signaling in the IBD development remains unclear. In this study, we were interested in the molecular mechanism of EZH2-mediated IBD progression.

**MATERIALS AND METHODS**

***Cell culture***

The NCM460 and fetal human colon (FHC) cell lines were maintained in the lab and were incubated at 37 °C with 5% CO2 in Dulbecco’s Modified Eagle Medium (GE, United States) containing fetal bovine serum (15%; GE Healthcare, Chicago, IL, United States), streptomycin (0.1 mg/mL), and penicillin (100 units/mL). The lentiviral plasmids carrying EZH2 short hairpin ribonucleic acid (shRNA) and the corresponding control shRNA were obtained (GenScript, Nanjing, China). The transfection in the cells was performed by Liposome 3000 (Invitrogen, Carlsbad, CA, United States). The EZH2 inhibitor GSK343 (Sigma, St. Louis, MO, United States) and JAK2 inhibitor TG101348 (Selleck, Houston, TX, United States) were used at the dose of 5 μmol/L. The TNF-α (Sigma) was used at the dose of 50 ng/mL.

***Clinical IBD samples***

The clinical IBD samples (*n* = 50) and non-IBD control cases (*n* = 50) were collected from The Third People's Hospital of Chengdu. The diagnosis of IBD was consistent with the standard combination of radiologic, histological, endoscopic, and clinical criteria. The application of the samples was under the approval of the patients and proved by the Ethics Committee of Sichuan Cancer Hospital & Institute. The patients provided their written informed consent to participate in this study.

***IBD mouse model***

C57BL/6 mice (female, 6–8 wk) were obtained from the Chinese Academy of Medical Sciences (Beijing, China). The mice were randomly divided into three groups: Water group; dextran sodium sulfate (DSS) group; DSS + shEZH2 group. The mice in DSS and DSS + shEZH2 groups were constructed by adding DSS (2.5%, MP Biomedicals, Santa Ana, CA, United States) to drinking water for 7 d, followed by normal drinking water for the remaining days. The mice in DSS + shEZH2 groups were intraperitoneally injected with lentiviral plasmids carrying EZH2 shRNA (GenScript). The mice received DSS (3%) to induce intestinal inflammation, and the natural death time of mice in the indicated groups within 15 d was recorded. The body weight was recorded at the indicated time. The colon length was measured and calculated using a ruler. The tissues were treated with 4% paraformaldehyde, and the decalcification was conducted in 5% nitric acid, followed by cutting into 5 μm sections. A set of alcohols was applied for the dehydration of the samples. Afterward, hematoxylin and eosin staining was performed in the slice samples of femoral head and then observed by microscope (BX-42; Olympus, Tokyo, Japan). The histologic score used to quantify the effect of EZH2 depletion in the mouse model by the pathologist was according to the criteria: Crypt architecture (normal, 0–severe crypt distortion with loss of entire crypts, 3), degree of inflammatory cell infiltration (normal, 0–dense inflammatory infiltrate, 3), muscle thickening (base of crypt sits on the muscularis mucosae, 0–marked muscle thickening, 3), crypt abscess (absent, 0–present, 1), and goblet cell depletion (absent, 0–present, 1)[1,2]. The levels of cytokines were measured by enzyme-linked immunosorbent assays (Sigma). Animal care was authorized by the Animal Ethics Committee. All experimental procedures with mice were performed in accordance and compliance with the regulations of the Laboratory Animal Welfare and Ethics Committee of Sichuan Cancer Hospital & Institute.

***Analysis of cell apoptosis***

About 2 × 105 NCM460 and FHC cells were plated on 6-well dishes. Cell apoptosis was assessed by employing the Annexin V-FITC Apoptosis Detection Kit (Sigma) using the manufacture’s instruction. Shortly, about 2 × 105 collected and washed cells collected by binding buffer and were dyed at 25 °C, followed by the flow cytometry analysis.

***Quantitative reverse transcription-polymerase chain reaction***

Total RNAs were extracted using TRIZOL (Invitrogen). The first-strand complementary (c)DNA was manufactured as the manufacturer's instruction (TaKaRa, Kyoto, Japan). The quantitative reverse transcription-polymerase chain reaction was carried out by applying SYBR-Green (TaKaRa). The primer sequences are as follows: EZH2 forward: 5′-AATCAGAGTACATGCGACTGAGA-3′, reverse: 5′-GCTGTATCCTTCGCTGTTTCC; JAK2 forward: 5′-GCCTTCTTTCAGAGCCATCAT-3′, reverse: 5′-GTGTAGGATCCCGGTCTTCAA-3′; Glyceraldehyde-3-phosphate dehydrogenase forward: 5′-AACGGATTTGGTCGTATTGGG-3′, reverse: 5′-CCTGGAAGATGGTGATGGGAT-3′.

***Western blot analysis***

Total proteins were extracted from the cells using radioimmunoprecipitation assay buffer (Cell Signaling Technology, Danvers, MA, United States) and quantified using the BCA Protein Quantification Kit (Abbkine, Wuhan, China). The proteins at same concentration were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to poly(vinylidene fluoride) membranes (Millipore, Burlington, MA, United States), followed by the incubation with 5% milk and with the primary antibodies at 4 °C overnight. The corresponding secondary antibodies (Boster, Wuhan, China) were used for incubating the membranes 1 h at room temperature, followed visualization by using chemiluminescence detection kit (Beyotime, Beijing, China). The primary antibodies applied in this study comprised EZH2 (Abcam, Cambridge, United Kingdom), Zona occludens 1 (ZO-1) (Abcam), claudin-5 (Abcam), occludin (Abcam), H3K27me3 (Abcam), JAK2 (Abcam), STAT3 (Abcam), p-JAK2 (Abcam), p-STAT3 (Abcam), EZH2 (Abcam), caspase3, cleaved-caspase3 (Abcam), and β-actin (Abcam).

***Chromatin immunoprecipitation analysis***

Chromatin immunoprecipitation (ChIP) was performed using a SimpleChIP Enzymatic ChIP Kit (Cell Signaling Technology) according to the manufacturer's instruction. Chromatin prepared from the cells in a 15 cm dish was used to determine total DNA input and was incubated overnight with specific antibodies or normal rabbit immunoglobulin G. Then, the binding DNA was analyzed by quantitative-polymerase chain reaction assays; the primer sequences were shown as above.

***Transepithelial electrical resistance measurements***

Transepithelial electrical resistance (TEER) measurement was used to analyze the barrier function of the intestine. About 2 × 105 cells/mL cells were layered on collagen-covered polycarbonate penetrable support supplements (Corning, Corning, NY, United States). The medium was replaced every 2 d. The production of the cells polarized monolayer at 3 wk was settled by monitoring and morphology of TEER by employing Millicell-ERS2 (Merck-Millipore). Delta-toxin was used to polarized monolayer cells at 37 °C.

***Statistical analysis***

The data were normally distributed. Data were expressed as mean ± SD, and the statistical analysis was conducted using GraphPad prism 7 (San Diego, CA, United States). The unpaired Student’s *t*-test was used to compare two groups, and the one-way analysis of variance was used to compare multiple groups. *P* < 0.05 was considered as statistically significant.

**RESULTS**

***The depletion of EZH2 inhibits DSS-induced colitis in vivo***

Firstly, we identified that the expression of EZH2 was enhanced in clinical IBD samples (*n* = 50) relative to healthy controls (*n* = 50) (Figure 1A). Meanwhile, we found that DSS enhanced EZH2 expression in mice, while the depletion of EZH2 by shRNA repressed the enhancement (Figure 1B and C). We then measured the effect of EZH2 on the DSS-induced colitis *in vivo*. We observed that the DSS treatment significantly resulted in a weight loss of the mice, which was attenuated by EZH2 depletion (Figure 1D). The colon length was reduced in the DSS-treated mice and was rescued by the EZH2 depletion in the system (Figure 1E and F). Meanwhile, the DSS treatment caused a decreased histological score in the mice, which was rescued by EZH2 depletion (Figure 1G). Moreover, the inflammatory cytokines, such as IL-6, IL-1β, and TNF-α, were enhanced in the DSS-treated mice, in which the depletion of EZH2 could reverse this effect (Figure 1H-J).

***EZH2 depletion attenuates apoptosis of colonic epithelial cells***

Then, the NCM460 and FHC colonic epithelial cells were treated with TNF-α or co-treated with TNF-α and EZH2 shRNA. We found that the expression of cleaved-caspase-3 was enhanced in the TNF-α-treated NCM460 and FHC cells, and the depletion of EZH2 was able to inhibit the enhancement in the cells (Figure 2A and B). Moreover, the TNF-α treatment induced the apoptosis of NCM460 and FHC cells, in which EZH2 knockdown could reverse this effect in the cells (Figure 2C and D).

***The depletion of EZH2 attenuates permeability of colonic epithelial cells***

Next, we further identified that the TEER was reduced by TNF-α treatment in the NCM460 and FHC cells, which was rescued by the depletion of EZH2 in the cells (Figure 3A and B). Consistently, the expression of permeability markers, including ZO-1, claudin-5, and occludin, was inhibited in the TNF-α-treated NCM460 and FHC cells, but the EZH2 depletion could rescue this phenotype in the cells (Figure 3C and D).

***EZH2 inactivates JAK2/STAT3 signaling in colonic epithelial cells***

Significantly, Western blot analysis showed that the depletion of EZH2 enhanced the expression and the phosphorylation of JAK2 and STAT3 in the NCM460 and FHC cells (Figure 4A and B). Meanwhile, the expression and the phosphorylation of JAK2 and STAT3 EZH2 inhibitor were induced by the EZH2 inhibitor GSK343 in the cells (Figure 4C and D).

***EZH2 inactivates JAK2 expression by regulating histone H3K27me3***

Furthermore, we observed that the H3K27me3 was reduced, along with the enhanced expression and the phosphorylation of JAK2 and STAT3, in the EZH2-knockdown NCM460 and FHC cells (Figure 5A and B). In addition, the depletion of EZH2 reduced the levels of H3K27me3 on the promoter of JAK2 in the cells (Figure 5C and D). Consistently, the mRNA expression of JAK2 was up-regulated by EZH2 depletion in the NCM460 and FHC cells (Figure 5E and F).

***EZH2 promotes apoptosis and permeability by inactivating JAK2/STAT signaling in colonic epithelial cells***

Next, we identified that EZH2 inhibitor GSK343 attenuated TNF-α-induced apoptosis of the NCM460 and FHC cells, and the JAK2 inhibitor TG101348 was able to rescue the phenotype in the cells (Figure 6A and B). Moreover, GSK343 rescued TNF-α-inhibited ZO-1, claudin-5, and occludin expression in the NCM460 and FHC cells, in which the co-treatment with TG101348 could reverse this effect in the system (Figure 6C and D).

**DISCUSSION**

IBD is a prevalent inflammatory gastrointestinal disease with high incidence. As a critical epigenetic regulator, EZH2 has been identified to contribute to IBD progression, but the mechanism remains unclear. In this study, we found that EZH2 promoted apoptosis and inflammatory response by inactivating JAK2/STAT signaling in IBD.

Several previous investigations have shown the function of EZH2 in the modulation of IBD. It has been reported that EZH2 is involved in the pathobiological mechanism of IBD progression[14]. Inhibiting EZH2 attenuates intestinal inflammation of IBD development[11]. EZH2 is an epigenetic regulator in colitis by inhibiting TNF-α-regulated apoptosis and inflammation in IBD[15]. EZH2 modulates intestinal necroptosis and inflammation in intestinal epithelial cells by c-jun N-terminal kinase signaling[16]. Targeting EZH2 enhances cAMP response element-binding protein to inhibit the ulcerative colitis progression[17]. It has been well-recognized that EZH2 presents a critical biological significance of in autoimmune disorders and cancer, and thereby targeting EZH2 is a promising therapeutic strategy in these diseases[18,19]. In this study, we demonstrated that the depletion of EZH2 inhibited DSS-induced colitis *in vivo.* EZH2 depletion attenuated apoptosis and permeabilityof colonic epithelial cells. Our data identified a critical role of EZH2 in the IBD progression, providing informative evidence of the function of EZH2 in modulating IBD development.

As essential cellular signaling in various pathological conditions, JAK2/STAT3 signaling plays critical role in IBD regulation. It has been found that V617F is able to up-regulate JAK2 expression in patients with IBD[20]. Sphk1 enhances ulcerative colitis by modulating JAK2/STAT3 signaling[21]. Renin-angiotensin system contributes to colonic inflammation by inducing helper T 17 activation through JAK2/STAT signaling[22]. A20 inhibits IBD *via* repressing nuclear factor-kappa B and STAT3 in mice[23]. Our mechanical studies showed that EZH2 inactivated JAK2 expression by regulating histone H3K27me3. EZH2 promoted apoptosis and permeability by inactivating JAK2/STAT signaling in colonic epithelial cells. These data discover an unreported association of EZH2 with JAK2/STAT signaling, elucidating a new mechanism involving EZH2 and JAK2/STAT in IBD pathogenesis.

**CONCLUSION**

In conclusion, we discovered that EZH2 contributed to apoptosis and inflammatory response by inactivating JAK2/STAT signaling in IBD. EZH2 is a promising target for treatment of IBD.

**ARTICLE HIGHLIGHTS**

***Research background***

Inflammatory bowel disease (IBD) is a prevalent worldwide health problem featured by relapsing, chronic gastrointestinal inflammation. Enhancer of zeste homolog 2 (EZH2) is a critical epigenetic regulator in different pathological models, such as cancer and inflammation. However, the role of EZH2 in the IBD development is still obscure.

***Research motivation***

To identify the effect of EZH2 on the IBD progression and the underlying mechanism.

***Research objectives***

To explore the role of EZH2 in the IBD progression and the underlying mechanism.

***Research methods***

The IBD mouse model was conducted by adding dextran sodium sulfate (DSS) and examining the effect of EZH2 on DSS-induced colitis in the model. The function of EZH2 in regulating apoptosis and permeability was evaluated by Annexin V-FITC Apoptosis Detection Kit, transepithelial electrical resistance analysis, and Western blot analysis of related markers, including Zona occludens 1, claudin-5, and occludin, in NCM460 and fetal human colon (FHC) cells. The mechanical investigation was performed by quantitative reverse transcription-polymerase chain reaction, Western blot analysis, and chromatin immunoprecipitation assays.

***Research results***

The colon length was inhibited in the DSS-treated mice and was enhanced by the EZH2 depletion in the system. DSS treatment caused a decreased histological score in the mice, which was reversed by EZH2 depletion. The inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin-6, and interleukin-1β, were induced in the DSS-treated mice, in which the depletion of EZH2 could reverse this effect. Moreover, the TNF-α treatment induced the apoptosis of NCM460 and FHC cells, in which EZH2 depletion could reverse this effect in the cells. Moreover, the depletion of EZH2 attenuated permeability of colonic epithelial cells. Mechanically, the depletion of EZH2 or EZH2 inhibitor GSK343 was able to enhance the expression and the phosphorylation of JAK2 and STAT3 in the NCM460 and FHC cells. Specifically, EZH2 inactivated JAK2 expression by regulating histone H3K27me3. JAK2 inhibitor TG101348 was able to reverse EZH2 knockdown-mediated colonic epithelial cell permeability and apoptosis.

***Research conclusions***

EZH2 contributes to apoptosis and inflammatory response by inactivating JAK2/STAT signaling in IBD.

***Research perspectives***

EZH2 may be applied as a potential target for IBD therapy.

**REFERENCES**

1 **Speca S**, Dubuquoy L. Chronic bowel inflammation and inflammatory joint disease: Pathophysiology. *Joint Bone Spine* 2017; **84**: 417-420 [PMID: 28062378 DOI: 10.1016/j.jbspin.2016.12.016]

2 **Sands BE**. Biomarkers of Inflammation in Inflammatory Bowel Disease. *Gastroenterology* 2015; **149**: 1275-1285.e2 [PMID: 26166315 DOI: 10.1053/j.gastro.2015.07.003]

3 **Franzosa EA**, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, Vatanen T, Hall AB, Mallick H, McIver LJ, Sauk JS, Wilson RG, Stevens BW, Scott JM, Pierce K, Deik AA, Bullock K, Imhann F, Porter JA, Zhernakova A, Fu J, Weersma RK, Wijmenga C, Clish CB, Vlamakis H, Huttenhower C, Xavier RJ. Gut microbiome structure and metabolic activity in inflammatory bowel disease. *Nat Microbiol* 2019; **4**: 293-305 [PMID: 30531976 DOI: 10.1038/s41564-018-0306-4]

4 **Shao BZ**, Wang SL, Pan P, Yao J, Wu K, Li ZS, Bai Y, Linghu EQ. Targeting NLRP3 Inflammasome in Inflammatory Bowel Disease: Putting out the Fire of Inflammation. *Inflammation* 2019; **42**: 1147-1159 [PMID: 30937839 DOI: 10.1007/s10753-019-01008-y]

5 **Graham DB**, Xavier RJ. Pathway paradigms revealed from the genetics of inflammatory bowel disease. *Nature* 2020; **578**: 527-539 [PMID: 32103191 DOI: 10.1038/s41586-020-2025-2]

6 **Wright EK**, Ding NS, Niewiadomski O. Management of inflammatory bowel disease. *Med J Aust* 2018; **209**: 318-323 [PMID: 30257634 DOI: 10.5694/mja17.01001]

7 **Halfvarson J**, Brislawn CJ, Lamendella R, Vázquez-Baeza Y, Walters WA, Bramer LM, D'Amato M, Bonfiglio F, McDonald D, Gonzalez A, McClure EE, Dunklebarger MF, Knight R, Jansson JK. Dynamics of the human gut microbiome in inflammatory bowel disease. *Nat Microbiol* 2017; **2**: 17004 [PMID: 28191884 DOI: 10.1038/nmicrobiol.2017.4]

8 **Schmidl C**, Delacher M, Huehn J, Feuerer M. Epigenetic mechanisms regulating T-cell responses. *J Allergy Clin Immunol* 2018; **142**: 728-743 [PMID: 30195378 DOI: 10.1016/j.jaci.2018.07.014]

9 **Henning AN**, Roychoudhuri R, Restifo NP. Epigenetic control of CD8+ T cell differentiation. *Nat Rev Immunol* 2018; **18**: 340-356 [PMID: 29379213 DOI: 10.1038/nri.2017.146]

10 **O'Meara MM**, Simon JA. Inner workings and regulatory inputs that control Polycomb repressive complex 2. *Chromosoma* 2012; **121**: 221-234 [PMID: 22349693 DOI: 10.1007/s00412-012-0361-1]

11 **Zhou J**, Huang S, Wang Z, Huang J, Xu L, Tang X, Wan YY, Li QJ, Symonds ALJ, Long H, Zhu B. Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation. *Nat Commun* 2019; **10**: 2427 [PMID: 31160593 DOI: 10.1038/s41467-019-10176-2]

12 **Duan R**, Du W, Guo W. EZH2: a novel target for cancer treatment. *J Hematol Oncol* 2020; **13**: 104 [PMID: 32723346 DOI: 10.1186/s13045-020-00937-8]

13 **Polgar N**, Csongei V, Szabo M, Zambo V, Melegh BI, Sumegi K, Nagy G, Tulassay Z, Melegh B. Investigation of JAK2, STAT3 and CCR6 polymorphisms and their gene-gene interactions in inflammatory bowel disease. *Int J Immunogenet* 2012; **39**: 247-252 [PMID: 22269120 DOI: 10.1111/j.1744-313X.2012.01084.x]

14 **Sarmento OF**, Svingen PA, Xiong Y, Sun Z, Bamidele AO, Mathison AJ, Smyrk TC, Nair AA, Gonzalez MM, Sagstetter MR, Baheti S, McGovern DP, Friton JJ, Papadakis KA, Gautam G, Xavier RJ, Urrutia RA, Faubion WA. The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD). *J Biol Chem* 2017; **292**: 706-722 [PMID: 27909059 DOI: 10.1074/jbc.M116.749663]

15 **Liu Y**, Peng J, Sun T, Li N, Zhang L, Ren J, Yuan H, Kan S, Pan Q, Li X, Ding Y, Jiang M, Cong X, Tan M, Ma Y, Fu D, Cai S, Xiao Y, Wang X, Qin J. Epithelial EZH2 serves as an epigenetic determinant in experimental colitis by inhibiting TNFα-mediated inflammation and apoptosis. *Proc Natl Acad Sci USA* 2017; **114**: E3796-E3805 [PMID: 28439030 DOI: 10.1073/pnas.1700909114]

16 **Lou X**, Zhu H, Ning L, Li C, Li S, Du H, Zhou X, Xu G. EZH2 Regulates Intestinal Inflammation and Necroptosis Through the JNK Signaling Pathway in Intestinal Epithelial Cells. *Dig Dis Sci* 2019; **64**: 3518-3527 [PMID: 31273598 DOI: 10.1007/s10620-019-05705-4]

17 **Li K**, Yang J, Lei XF, Li SL, Yang HL, Xu CQ, Deng L. EZH2 inhibition promotes ANGPTL4/CREB1 to suppress the progression of ulcerative colitis. *Life Sci* 2020; **250**: 117553 [PMID: 32194081 DOI: 10.1016/j.lfs.2020.117553]

18 **Yang YX**, Shen HH, Cao F, Xie LY, Zhu GL, Sam NB, Wang DG, Pan HF. Therapeutic potential of enhancer of zeste homolog 2 in autoimmune diseases. *Expert Opin Ther Targets* 2019; **23**: 1015-1030 [PMID: 31747802 DOI: 10.1080/14728222.2019.1696309]

19 **Stazi G**, Zwergel C, Mai A, Valente S. EZH2 inhibitors: a patent review (2014-2016). *Expert Opin Ther Pat* 2017; **27**: 797-813 [PMID: 28394193 DOI: 10.1080/13543776.2017.1316976]

20 **Asadzadeh-Aghdaei H**, Mashayekhi K, Koushki K, Azimzadeh P, Rostami-Nejad M, Amani D, Chaleshi V, Haftcheshmeh SM, Sahebkar A, Zali MR. V617F-independent upregulation of JAK2 gene expression in patients with inflammatory bowel disease. *J Cell Biochem* 2019; **120**: 15746-15755 [PMID: 31069840 DOI: 10.1002/jcb.28844]

21 **Liu J**, Jiang B. Sphk1 promotes ulcerative colitis *via* activating JAK2/STAT3 signaling pathway. *Hum Cell* 2020; **33**: 57-66 [PMID: 31606874 DOI: 10.1007/s13577-019-00283-z]

22 **He L**, Du J, Chen Y, Liu C, Zhou M, Adhikari S, Rubin DT, Pekow J, Li YC. Renin-angiotensin system promotes colonic inflammation by inducing TH17 activation *via* JAK2/STAT pathway. *Am J Physiol Gastrointest Liver Physiol* 2019; **316**: G774-G784 [PMID: 30995068 DOI: 10.1152/ajpgi.00053.2019]

23 **Lee SH**, Lee HR, Kwon JY, Jung K, Kim SY, Cho KH, Choi J, Lee HH, Lee BI, Jue DM, Cho ML. A20 ameliorates inflammatory bowel disease in mice *via* inhibiting NF-κB and STAT3 activation. *Immunol Lett* 2018; **198**: 44-51 [PMID: 29608924 DOI: 10.1016/j.imlet.2018.03.015]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of Sichuan Cancer Hospital.

**Institutional animal care and use committee statement:** All experimental procedures with mice were performed in accordance and compliance with the regulations of the Laboratory Animal Welfare and Ethics Committee of Sichuan Cancer Hospital & Institute.

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** March 7, 2021

**First decision:** March 27, 2021

**Article in press:** April 28, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): C


Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Chen P, Gatti S **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:** Wang LL


**Figure Legends**










**Figure 1 The depletion of enhancer of zeste homolog 2 inhibits dextran sodium sulfate-induced colitis *in vivo*.** A: The expression of enhancer of zeste homolog 2 (EZH2) was measured by quantitative real-time polymerase chain reaction in clinical inflammatory bowel disease (IBD) samples (*n* = 50) and healthy controls (*n* = 50); B-J: The IBD mouse model was conducted by adding dextran sodium sulfate (DSS). The mice were intraperitoneally injected with lentiviral plasmids carrying EZH2 shRNA; B: The expression of EZH2 was detected by quantitative real-time polymerase chain reaction in the mice; C: The protein levels of EZH2 were analyzed by Western blot in the mice; D: The body weight in the mice; E and F: Colon length of the mice; G: representative hematoxylin and eosin staining of distal colon sections; H-J: Colonic inflammatory cytokines in the mice. *n* = 10, mean ± SD. a*P* < 0.05; b*P* < 0.01; c*P* < 0.001. TNF-α: Tumor necrosis factor-α; IL: Interleukin.










**Figure 2** **Enhancer of zeste homolog 2 depletion attenuates apoptosis of colonic epithelial cells.** The NCM460 and fetal human colon (FHC) cells were treated with tumor necrosis factor-α (TNF-α), or co-treated with TNF-α and enhancer of zeste homolog 2 (EZH2) short hairpin RNA. A and B: Western blot analysis of the caspase3 and cleaved-caspase3 expression; C and D: Flow cytometry analysis of the cell apoptosis. *n* = 3, mean ± SD, b*P* < 0.01.









**Figure 3** **The depletion of enhancer of zeste homolog 2 attenuates permeability of colonic epithelial cells.** The NCM460 and fetal human colon (FHC) cells were treated with tumor necrosis factor-α (TNF-α), or co-treated with TNF-α and enhancer of zeste homolog 2 (EZH2) short hairpin RNA. A and B: Transepithelial electrical resistance (TEER) measurement of the transepithelial electrical resistance levels; C and D: Western blot analysis of the Zona occludens 1 (ZO-1), claudin-5, and occludin expression. *n* = 3, mean ± SD, b*P* < 0.01.




**Figure 4** **Enhancer of zeste homolog 2 inactivates janus kinase 2/ signal transducer and activator of transcription signaling in colonic epithelial cells.** A and B: The NCM460 and fetal human colon (FHC) cells were treated with control shRNA or enhancer of zeste homolog 2 (EZH2) short hairpin RNA. Western blot analysis of the Janus kinase 2 (JAK2), Signal transducer and activator of transcription 3 (STAT3), and EZH2 expression and JAK2 and STAT3 phosphorylation; C and D: The NCM460 and FHC cells were treated with GSK343 (5 μM). Western blot analysis of the JAK2, STAT3, and EZH2 expression and JAK2 and STAT3 phosphorylation. *n* = 3.



**Figure 5** **Enhancer of zeste homolog 2 inactivates janus kinase 2 expression by regulating histone H3K27me3.** A-E: The NCM460 and fetal human colon (FHC) cells were treated with control short hairpin RNA or enhancer of zeste homolog 2 (EZH2) short hairpin RNA; A and B: Western blot analysis of the H3K27me3, Janus kinase 2 (JAK2), signal transducer and activator of transcription 3 (STAT3), and EZH2 expression and JAK2 and STAT3 phosphorylation; C and D: Chromatin immunoprecipitation (ChIP) assays of the JAK2 promoter using H3K27me3 antibody; E and F: The quantitative real-time polymerase chain reaction assays of JAK2 messenger RNA expression. *n* = 3, mean ± SD, b*P* < 0.01.





**Figure 6 Enhancer of zeste homolog 2 promotes apoptosis and permeability by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in colonic epithelial cells.** The tumor necrosis factor-α (TNF-α)-treated NCM460 and fetal human colon (FHC) cells were treated with GSK343 (5 μM) or co-treated with GSK343 (5 μM) and TG101348 (5 μM). A and B: Flow cytometry analysis of the cell apoptosis; C and D: Western blot analysis of the Zona occludens 1 (ZO-1), claudin-5, and occludin expression. *n* = 3, mean ± SD. b*P* < 0.01.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**